In the News

Phoenix Business Journal Covers $2.4 Million Seed Funding, Profiles CND

Phoenix Business Journal Covers $2.4 Million Seed Funding, Profiles CND

CND Life Sciences continues to build its presence as an exciting medical technology start-up. Phoenix Business Journal published a profile of the company this week along with the news of its freshly completed $2.4 million seed funding round. CND has big plans for growth as it looks to move to a new lab space in Scottsdale and fortify its sales and marketing efforts—all with the goal of helping doctors diagnose Parkinson’s disease, dementia with Lewy bodies, and other synucleinopathies with its innovative, skin-based Syn-One Test™.

Courtesy of Phoenix Business Journal

READ THE ARTICLE
CND Life Sciences

CND Life Sciences

CND Life Sciences is the creator of the Syn-One Test™, the world’s first commercially available test to visualize abnormal, phosphorylated alpha-synuclein in cutaneous nerve fibers. The test is an objective, evidence-based diagnostic tool to aid in the diagnosis of Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, pure autonomic failure, or REM sleep behavior disorder.